Dupixent and CTCL: the new MDL is here, but the paperwork still matters most

If Dupixent is part of your family's CTCL story, the biggest update is
simple: the federal cases now have one courtroom for pretrial work.

The U.S. Judicial Panel on Multidistrict Litigation created MDL No. 3180
on June 4, 2026. The case is called In re: Dupixent (Dupilumab) Products
Liability Litigation. It is in the District of New Jersey before Judge
Zahid N. Quraishi.

That does not mean the court has ruled that Dupixent caused anyone's
cancer. It has not. The order just means the Panel found enough overlap
in the lawsuits to centralize them. Instead of 12 districts handling the
same document requests and expert fights separately, one judge will
manage the pretrial track.

That is usually how a drug MDL begins. Quietly. With scheduling orders,
leadership fights, document preservation, plaintiff fact sheets, defense
fact sheets, and arguments about what the science can and cannot prove.

What the transfer order actually says

The JPML order says most plaintiffs used Dupixent, commonly prescribed
for atopic dermatitis, and were later diagnosed with cutaneous T-cell
lymphoma, or CTCL. Some claims were brought by spouses or survivors.

The Panel listed the shared questions in plain terms. Does the
scientific literature show a causal link between Dupixent and CTCL? If
there is a link, when should Sanofi, Regeneron, and related defendants
have known? Were the warnings adequate?

Those questions are still unanswered. They are the fight.

The order counted 15 actions and seven potential tag-along actions
across 12 districts at the time of centralization. The July 1, 2026 JPML
pending MDL report also lists MDL 3180 in New Jersey, docket
3:26-md-3180, with Judge Quraishi assigned.

So this is early litigation. Not a settlement announcement. Not a
verdict. Not proof that every CTCL diagnosis after Dupixent belongs in a
lawsuit. Early does not mean weak, but it does mean families should be
careful with claims they read online.

Why this is not a simple eczema story

CTCL can be hard to spot. Some forms, including mycosis fungoides and
Sezary syndrome, may look like eczema or dermatitis at first. People can
go through creams, repeat visits, biopsies, second opinions, and months
of uncertainty before someone names the disease.

That diagnostic problem sits right in the middle of the Dupixent cases.

Some lawsuits allege Dupixent caused CTCL or accelerated it. Others
focus on whether the drug unmasked a cancer that was already there, or
whether treatment delayed the right diagnosis because the symptoms were
being viewed as stubborn eczema. Those are different theories. A good
case review has to separate them instead of mashing them together.

Doctors are still careful about the science. A 2025 AAAAI Ask the Expert
discussion pointed to one database study reporting a higher CTCL risk in
atopic dermatitis patients prescribed dupilumab. It also pointed to
another analysis that argued the Dupixent-CTCL association may be
explained by the drug unmasking preexisting CTCL. The same AAAAI
discussion said there are no prospective randomized trials that
definitively answer the question.

That is not very satisfying for a patient. It is, however, honest.

The FDA label tells only part of the story

Dupixent's April 2026 FDA prescribing information lists many approved
uses: atopic dermatitis, asthma, chronic rhinosinusitis with nasal
polyps, eosinophilic esophagitis, prurigo nodularis, COPD with an
eosinophilic phenotype, chronic spontaneous urticaria, bullous
pemphigoid, and allergic fungal rhinosinusitis.

The label also lists warnings and precautions, including
hypersensitivity, eye problems, eosinophilic conditions, problems tied
to abrupt corticosteroid reduction, psoriasis, joint pain, parasitic
infections, and live vaccines.

The lawsuits ask a narrower question: should patients and doctors have
been warned differently about possible T-cell lymphoma issues? That
answer will depend on company records, medical literature, expert
testimony, and patient histories. It will not be solved by one label
screenshot.

What to save now

If you or someone in your family used Dupixent and later received a CTCL
diagnosis, save the records before they disappear into old portals and
closed practices.

Start with the basics:

• Dupixent prescription dates, dose history, pharmacy records, and
  injection schedule
• dermatology notes from before the first Dupixent dose
• photos of skin changes, if you have them, with approximate dates
• biopsy reports and dermatopathology notes
• pathology slides or information on where the slides are stored
• oncology records showing the exact CTCL subtype
• records mentioning mycosis fungoides, Sezary syndrome, or another CTCL
  diagnosis
• messages to doctors about worsening rash, plaques, itching, lesions,
  or changing symptoms
• insurance records showing visits, biopsies, lab work, or cancer
  treatment
• death certificate and estate paperwork if the patient died

The biopsy material can matter a lot. A diagnosis date helps, but it may
not be enough. Lawyers and medical reviewers often need the pathology
report and, when possible, the underlying slides or tissue-block
information.

Who should consider asking questions

A Dupixent CTCL review may make sense if the patient used Dupixent and
was later diagnosed with CTCL, mycosis fungoides, Sezary syndrome, or a
related CTCL subtype.

It may also be worth asking questions if the person had a long history
of presumed eczema or dermatitis that changed, worsened, or failed to
respond as expected before CTCL was diagnosed.

Do not stop Dupixent, restart it, or change any prescribed treatment
because of this article. That is a medical decision for the treating
doctor. The legal review looks backward at timing, warnings, records,
diagnosis, and harm.

For now, MDL 3180 is a CTCL-focused Dupixent proceeding in New Jersey.
The science will be contested. The next court steps will likely be
organizational, not dramatic. Families can still do something useful
today: save the records while they are still easy to get.

Attorney advertising / informational notice: This article is general
information, not legal advice. Reading it does not create an attorney-
client relationship. Lawsuit eligibility depends on medical records,
exposure history, filing deadlines, jurisdiction, and other facts. Past
results do not guarantee any outcome.